The FDA's approval of Medtronic's Evolut FX+ TAVR system is a significant positive development for the company. This approval not only enhances Medtronic's product portfolio but also strengthens its position in the medical devices market, particularly in the cardiovascular segment. The approval is likely to boost investor confidence in Medtronic's innovation capabilities and its ability to navigate the regulatory landscape successfully. Consequently, this news is expected to have a positive short-term impact on Medtronic's stock price as it reflects the company's potential for growth and profitability in a high-demand healthcare sector.